Established science names five main dementia subtypes and shows mixed disease is common after age 80. What remains uncertain in 2026 is the exact subtype mix in a living person and which care approach fits best.
The National Institute on Aging defines dementia as loss of thinking, remembering, and reasoning severe enough to interfere with daily life NIA's dementia definition. The Alzheimer's Association reports 7.4 million Americans age 65 and older live with clinical Alzheimer's dementia in 2026. That is about 1 in 9 older adults.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- The five recognized subtypes
- Why mixed disease is hard to diagnose
- What biomarkers and blood tests can show
- Which gaps shape care in 2026
- Practical steps when memory concerns arise
The five recognized subtypes
NINDS and NIA list Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal disorders, and mixed dementia. Alzheimer's is most common and vascular disease ranks second. Mixed dementia means more than one disease process affects the brain at the same time.
Brain-autopsy studies find most people age 80 and older with dementia had mixed disease. One study found 78% had two or more neurodegenerative or vascular pathologies, as summarized by NIA sources. Lifetime risk is about 20% for women and 10% for men, according to the Alzheimer's Association 2026 report. That overlap makes exact labels harder for older adults seeking clear answers.
Why mixed disease is hard to diagnose
Clinical diagnosis means the doctor's judgment during life, before any brain-autopsy confirmation. According to a Frontiers in Aging Neuroscience study of NACC data, detection of combined Alzheimer's plus Lewy-body disease was very low in 1,920 participants from 2005 to 2019. CDR means Clinical Dementia Rating, where higher scores mean more severe impairment.
Sensitivity was only 2.7% at CDR 0.5 and rose only to 4.7% at CDR 3.0. Early symptoms often overlap, so memory, attention, and movement changes do not point to one subtype alone. Families should expect follow-up visits and revised diagnoses when new symptoms appear.
What biomarkers and blood tests can show
The 2024 Alzheimer's Association Workgroup criteria, building on the 2018 NIA-AA framework, define Alzheimer's biologically. Abnormal Core 1 markers include amyloid PET, CSF Aβ42/40, or plasma p-tau217, even without symptoms. That summary comes from Frontiers in Aging Neuroscience describing Jack and colleagues.
The Food and Drug Administration cleared Fujirebio Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio on May 16, 2025 summary of FDA actions. The test is for adults 55 and older with cognitive symptoms seen in specialty care. It is not for screening and not a stand-alone diagnosis.
Which gaps shape care in 2026
The NIA summit summary says no single treatment or care model fits all, and lists data silos and access barriers among priorities federal agency update on the summit. NIA convened the virtual summit on March 17-19, 2026, with the summary released in August 2026.
An NIH-led NINDS-NIA genetics study found five genes and structural variants that raise Lewy body dementia risk. The NIA news report links that risk to genetic overlap with both Parkinson's and Alzheimer's diseases. Overlap helps explain why symptoms and test results often cross subtype lines.
Practical steps when memory concerns arise
Use visits to document how symptoms affect daily tasks, work, driving, and household safety. Clear examples help specialists judge severity and choose follow-up tests. Bring a written list of three daily tasks that have become harder and share it at each visit.
- Note when problems began and which daily activities now need help
- Bring medications, sleep, mood, and medical history to specialty care
- Ask whether biomarker testing fits adults 55 and older with symptoms and what limits apply
- Plan support for daily tasks while diagnosis remains incomplete
You Might Also Like
- Privacy and Data Access Gaps in 2026 Dementia Research: What Is Established and What Remains Uncertain for Adults With Memory Concerns
- NHATS and NSOC Dementia Care Data Priorities in 2026: What Is Established and What Remains Uncertain for Adult Children
- Smoking and Alcohol in the 2026 WHO Dementia Guideline: What Is Established and What Is Still Being Studied for Adults Over 65





